An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
ppublish
Résumé
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M
Identifiants
pubmed: 38478629
doi: 10.1126/scitranslmed.adi0979
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM